Latest Breaking News On - Interim chief financial officer - Page 2 : comparemela.com

DynaResource, Inc Announces Executive Leadership Change

Mr. Rohan Hazelton Appointed as President, CEO, Interim CFO and Director of DynaResource, Inc.IRVING, TX / ACCESSWIRE / June 3, 2024 / DYNR-DynaResource, Inc. (OTCQX:DYNR) ("DynaResource", or "the Company")

San jose de graciaUnited statesUnited kingdomWheaton riverRohan hazeltonBradj saulterPhil roseBrent omlandRene mladosichNorzinc ltdDynr dynaresource incCompany equity incentive planCompany board of directorsSecurities exchangeHarvard universityOcean partners united kingdom

DynaResource, Inc Announces Executive Leadership Change

DynaResource, Inc Announces Executive Leadership Change
bignewsnetwork.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bignewsnetwork.com Daily Mail and Mail on Sunday newspapers.

San jose de graciaUnited statesWheaton riverUnited kingdomBradj saulterRohan hazeltonRene mladosichBrent omlandPhil roseNational instrumentWheaton river mineralsCompany equity incentive planDynr dynaresource incNorzinc ltdExchange commissionDynaresource inc

DynaResource, Inc Announces Executive Leadership Change

DynaResource, Inc Announces Executive Leadership Change
pr-inside.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pr-inside.com Daily Mail and Mail on Sunday newspapers.

United kingdomWheaton riverSan jose de graciaUnited statesRohan hazeltonPhil roseBrent omlandRene mladosichExchange commissionDynaresource incNews networkWheaton river mineralsCompany equity incentive planHarvard universityNational instrumentCompany board of directors

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesNorth carolinaNew yorkFrance generalAshleyr robinsonArthur strilMark frattiniPascalyne wilsonPatricia sosa navarroAmerican society of hematologyCellectis the company euronext growthEuropean medicines agencyEuropean unionSecurities exchange commissionCommittee for orphan medicinal productsEuropean commission

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell

United statesNorth carolinaFrance generalNew yorkPatricia sosa navarroPascalyne wilsonMark frattiniAshleyr robinsonArthur strilEuropean medicines agencyCellectis the company euronext growthAmerican society of hematologyEuropean commissionSecurities exchange commissionEuropean unionCommittee for orphan medicinal products